Regeneron Pharmaceuticals Inc (NAS:REGN)
$ 975.74 7.74 (0.8%) Market Cap: 107.50 Bil Enterprise Value: 98.84 Bil PE Ratio: 28.82 PB Ratio: 3.98 GF Score: 94/100

Q4 2019 Regeneron Pharmaceuticals Inc Earnings Call Transcript

Feb 06, 2020 / 01:00PM GMT
Release Date Price: $389.85 (+4.75%)
Operator

Welcome to Regeneron Pharmaceuticals Q4 2019 Earnings Conference Call. My name is Sylvia, and I'll be your operator for today's call. (Operator Instructions) Please note that this conference is being recorded.

I will now turn the call over to Justin Holko. Justin, you may begin.

Justin Holko
Regeneron Pharmaceuticals, Inc. - VP of IR

Thank you, Sylvia. Good morning, good afternoon and good evening to everyone listening around the world. Thank you for your interest in Regeneron, and welcome to the fourth quarter 2019 conference call. An archive of this webcast will be available on our website. Joining me today are Leonard Schleifer, Founder, President and Chief Executive Officer; George Yancopoulos, Founding Scientist, President and Chief Scientific Officer; Marion McCourt, Senior Vice President and Head of Commercial; and Bob Landry, Executive Vice President and Chief Financial Officer.

After our prepared remarks, we will open the call for Q&A. I would also like to remind you that remarks made on today's call include forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot